All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Janssen Biotech Inc. and Yuhan Corp. have synthesized substituted aminopyridine compounds acting as EGFR (HER1; erbB1) (mutant) inhibitors reported to be useful for the treatment of cancer and immunological disorders.
